Medicines Co. (MDCO) Halts Development of MDCO-216
- Squarespace, Inc. (SQSP) To Go Private For $44/shr In Cash With Permira
- It's time to buy the AI dip in chip stocks: Jefferies
- Xponential Fitness (XPOF) removes Anthony Geisler from his duties and suspended him indefinitely as CEO
- Google stock slips on Apple-ChatGPT rumors; OpenAI to reveal updates
- Axalta Coating Systems (AXTA) to Acquire The CoverFlexx Group for Up to $295M Cash
- Intel, Arm, Apple, GameStop rise premarket; Bristol Myers falls
- Midday movers: Novavax, Nvidia, Sweetgreen rise; Moderna, Yelp fall
- After-hours movers: Akamai Technologies, Unity, Macrogenics and more
- Midday movers: Roblox, Airbnb fall; Trade Desk, AppLovin and Bumble rise
- After-hours movers: Robinhood, AppLovin rise; Airbnb, Arm fall, and more
The Medicines Company Discontinues Development of MDCO-216, its Investigational Cholesterol Efflux Promoter
November 7, 2016 4:30 PM ESTTop-line efficacy data from the MILANO-PILOT trial, which enrolled 126 patients, provide insufficient basis for further investment by the Company
Discontinuation will enable the Company to reallocate and focus substantial additional capital onto the development of its PCSK9 synthesis inhibitor
Results from the MILANO-PILOT trial will be presented in the Late-Breaking Clinical Trial Session at American Heart Association Scientific Sessions 2016
PARSIPPANY, N.J.--(BUSINESS WIRE)-- The Medicines Company (NASDAQ: MDCO) announced today the immediate discontinuation of the clinical development program for MDCO-216, its investigational... More